Study: Survival Not Affected by Discordant Pathology in High-Grade UTUC
Among patients with high-grade UTUC, overall survival did not differ significantly between patients with discordant vs concordant pathologies.
SUO 2019
Long-Term Outcomes After Prostate Surgery Good Despite Detectable PSA
Following radical prostatectomy, prostate cancer-specific survival at 10 years was 91% for patients with detectable PSA and 99% for those with undetectable PSA, a study found.
Novel 3-Drug Regimen Shows Promise for BCG-Refractory NMIBC
Patients who received intravesical docetaxel, gemcitabine, and cisplatin for BCG-refractory nonmuscle-invasive bladder cancer had initial downgrading, downstaging, or both.
Cytoreductive Nephrectomy Offers a Survival Edge in mRCC
Patients receiving modern immunotherapy for metastatic renal cell carcinoma have a decreased risk of death if they also undergo cytoreductive nephrectomy, a study found.
Risk Factors for Reoperation After Radical Cystectomy Identified
Higher body mass index, a history of chronic obstructive pulmonary diseases, and black race are associated with an increased risk of reoperation within 30 days of racial cystectomy, a study found.
Chemotherapy First Is Superior in mCRPC Cases
A study found better cancer-specific survival among men with metastatic castration-resistant prostate cancer who received chemo before antiandrogens.
SUO 20th Annual Scientific Meeting Convenes
The Society of Urologic Oncology (SUO) convenes its 20th Annual Scientific Meeting in Washington, DC, from December 4 to 6 at the Renaissance Washington DC Downtown Hotel.
-
Loading...
-
Loading...
Next post in SUO 2019
